Androgens; Lipids; Testosterone; Adult; Aged; Aging; Androgens/therapeutic use; Andropause/drug effects; Humans; Hypogonadism/blood; Hypogonadism/drug therapy; Lipids/blood; Male; Testosterone/therapeutic use; Endocrinology, Diabetes and Metabolism; Endocrinology; General Medicine
Résumé :
[en] The decrease in serum bioavailable testosterone may be responsible for the catabolic sequelae noticed in the aging man (decrease in libido, decrease in muscle mass, osteoporosis and increase in adiposity). After a brief review of androgen and lipid metabolism as well as their modifications with aging, we discuss current knowledge of the effects of androgen substitution on the lipid profile in hypogonadal men. The results of studies concerning the effect of androgen substitution therapy on lipids are conflicting but might be favorable. The small decrease in high-density lipoprotein cholesterol observed when administering standard dosages of testosterone is accompanied by a significant decrease in total cholesterol (CT) and low-density lipoprotein cholesterol. A counterbalancing of these effects plausibly accounts for the absence of increase cardiovascular risk. The currently available preparations are oral, injectable or transdermal formulations of natural testosterone. The development of new androgen preparations that are more potent, metabolically stable and tissue-specific will improve therapeutic benefits and reduce side effects.
Disciplines :
Endocrinologie, métabolisme & nutrition
Auteur, co-auteur :
Schleich, FLorence ; Université de Liège - ULiège > Département des sciences précliniques MI > Anatomie et cytologie pathologiques
Langue du document :
Anglais
Titre :
Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male.
Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD & Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. Journal of Clinical Endocrinology and Metabolism 1998 83 1886-1892.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanna J, Rosen CJ & Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999 84 2467-2653.
Jeffcoate SL, Brocks RV, Lin NY, London DR, Prunty FT & Spathis GS. Androgen production in hypogonadal men. Journal of Endocrinology 1967 37 401-411.
Wheeler MJ. Determination of bio-available testosterone. Annals of Clinical Biochemistry 1995 32 345-357.
Lejeune H, Déchaud H & Pugeat M. Contribution of bioavailable testosterone assay for the diagnosis of androgen deficiency in elderly men. Annals of Endocrinologiey 2003 64 117-125.
Liu P, Death A & Handelsman D. Androgens and cardiovascular disease. Endocrine Reviews 2003 24 313-340.
Vermeulen A, Rubens R & Verdonck L. Testosterone secretion and metabolism in male senescence. Journal of Clinical Endocrinology and Metabolism 1972 34 730- 735.
Bremner WJ & Prinz PN. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. Journal of Clinical Endocrinology and Metabolism 1983 56 1278-1281.
Tenover JS, Matsumoto AM, Plymate SR & Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. Journal of Clinical Endocrinology and Metabolism 1987 65 1118-1126.
Gray A, Berlin JA, McKinlay JB & Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. Journal of Clinical Epidemiology 1991 44 671-684.
Ferrini RL & Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. American Journal of Epidemiology 1998 147 750-754.
Purifoy FE, Koopmans LH & Mayes DM. Age differences in serum androgen levels in normal adult males. Human Biology 1981 53 499-511.
Zmuda JM, Cauley JA & Kriska A. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. American Journal of Epidemiology 1997 146 609-617.
Morley JE, Kaiser FE & Perry HM 3rd. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997 46 410-413.
Harman SM, Metter EJ, Tobin JD, Pearson J & Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Journal of Clinical Endocrinology and Metabolism 2001 86 724-731.
Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ & McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. Journal of Clinical Endocrinology and Metabolism 2002 87 589-598.
Gray A, Feldman HA, McKinley JB & Longcope C. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism 1991 73 1016-1025.
Desylpere JP & Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. Journal of Clinical Endocrinology and Metabolism 1984 59 955-962.
Vermeulen A, Kaufman JM & Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. Journal of Clinical Endocrinology and Metabolism 1996 81 1821-1826.
Feldman HA, McKinlay JB & Longcope C. Hypogonadism: correlates in a large random sample of Massachusetts men. Proceedings of the 79th Annual Meeting of the Endocrine Society, 1997, pp 1-317.
Neaves WB, Johnson L, Porter JC, Parker CR Jr & Petty CS. Leydig cell numbers, daily sperm production and serum gonadotrophin levels in aging men. Journal of Clinical Endocrinology and Metabolism 1984 59 756-763.
Vermeulen A & Desylpere JP. Intratesticular unconjugated steroids in elderly men. Journal of Steroid Biochemistry 1986 24 1079-1089.
Suoranta H. Changes in small blood vessels of the adult human testes in relation to age and some pathological conditions. Virchows Archiv (Pathological Anatomy and Histopathology) 1971 352 765-781.
Vermeulen A, Desylpere JP & Kaufman JM. Influence of antiopioids and luteinizing hormone pulsatility in aging men. Journal of Clinical Endocrinology and Metabolism 1989 68 68-72.
Winters SJ, Sherins RJ & Troen P. The gonadotropin suppressive activity of androgens is increased in elderly men. Metabolism 1984 33 1052-1059.
Desylpere JP & Vermeulen A. Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. Journal of Clinical Endocrinology and Metabolism 1989 68 68-72.
Bremner WJ, Vitiello MV & Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. Journal of Clinical Endocrinology and Metabolism 1983 56 1278-1281.
Meikle AW, Stanish WM, Taylor N, Edwards CQ & Bishop CT. Familial effects on plasma sex-steroid content in man: testosterone, estradiol and sex hormone-binding-globulin. Metabolism 1982 31 6-9.
Von Eckardstein A, Nofjer JR & Assmann G. HDL and coronary heart disease: role of cholesterol efflux and reverse cholesterol transport. Atheriosclerosis, Thrombosis, and Vascular Biology 2001 20 13-27.
Bagatell CJ & Bremmer WJ. Androgen and progestagen effects on plasma lipids. Progress in Cardiovascular Diseases 1995 38 255-271.
Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D & Krone W. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999 48 590-596.
Uyanik BS, Ari Z. Gumus B, Yigitoglu MR & Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Japanese Heart Journal 1997 38 73-82.
Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P & Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. Journal of Gerontology. Series A, Biological Sciences and Medical Sciences 2003 58 618-625.
Ly L, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ & Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 4078-4088.
Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW & Mazer NA. Long-term efficacity and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clinical Endocrinology 1997 47 727-737.
Wang C, Swerdloff R, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T & Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Journal of Clinical Endocrinology and Metabolism 2000 85 2839-2853.
Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B & Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. Journal of Gerontology. Series A, Biological Sciences and Medical Sciences 2002 57 460-465.
Snyder PJ, Peachey H, Berlin JA, Rader D, Usher D, Loh L, Hannoush P, Dlewati A, Holmes JH, Santanna. J & Strom BL Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. American Journal of Medicine 2001 111 255-260.
Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M & Sadowski Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996 21 35-43.
Dobs AS, Meikle AW, Aver S, Sanders SW, Caramelli KE & Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1999 84 3469-3478.
Kenny AM, Prestwood KM & Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocrine Research 2000 26 153-168.
Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M & Perry HM Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. Journal of the American Geriatrics Society 1993 41 149-152.
Ellvin FM, Plunkett-Reid K & Rumilla AE. The long-term beneficial effect of low-dose testosterone in the aging male. Proceedings of the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, USA, 1997. Abstract P236.
Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P & Ross C. Testosterone replacement in older hypogonadal men - a 12 month randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 1997 82 1661-1667.
Barret-Connor E. Testosterone, HDL cholesterol, and cardiovascular disease in men. In Pharmacology, Biology, and Clinical Applications of Androgens, pp 215-223. Eds S Bhasin, HL Gabelnick, JM Spieler, RS Swerdloff, C Wang & C Kelly. New York: Wiley, 1996.
Tan KCB, Shiu SWN & Pang RWC. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-1 containing lipoproteins. Clinical Endocrinology 1998 48 187-194.
Hajjar RR, Kaiser FE & Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males. A retrospective analysis. Journal of Clinical Endocrinology and Metabolism 1997 82 3793-3796.
Tenover JS. Effects of testosterone supplementation in the aging male. Journal of Clinical Endocrinology and Metabolism 1992 75 1092-1098.
Whistel EA, Boyko EJ, Matsumoto AM, Anawalt BD & Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. American Journal of Medicine 2001 111 261-269.
Berg G, Schreier L, Geloso G, Otero P, Nagelberg A & Levalle O. Impact on lipoprotein proffle after long-term testosterone replacement in hypogonadal men. Hormone and Metabolic Research 2002 34 87-92.
Rabijewski M, Adamkiewicz M & Zgliczynski S. The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men. Polskie Archiwum Medycyny Wewnetrznej 1998 100 212-221.
Ozata M, Yildirimkaya M, Bulur M, Bingol N, Beyhan Z, Corakci A, Bolu E & Gundogan MA. Effects of gonadotropin and testosterone treatments on lipoprotein (a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. Journal of Clinical Endocrinology and Metabolism 1996 81 3372-3378.
Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE & Mazer NA. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. Journal of Clinical Endocrinology and Metabolism 2001 86 1026-1033.
Kantor MA, Bianchi A, Bernier D, Sady SP & Thompson PD. Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Medicine and Science in Sports and Exercise 1985 17 462-465.
Heiss G, Johnson NJ, Reiland S, Davis CE & Tyroler HA. The epidemiology of plasma high density lipoproteins cholesterol levels. Circulation 1980 62 (Suppl) 116-136.
Xu X, De Pergola G & Bjorntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990 126 1229-1234.
Friedle KE, Hannan C, Jones RE & Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990 39 69-74.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM & Ockene J. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Wome's Health Initiative randomized controlled-trial. Journal of the American Medical Association 2002 288 321-333.
Hauner H, Stangl K, Burger K, Busch U, Blomer H & Pfeiffer EF. Sex hormone concentrations in men with angiographically assessed coronary artery disease - relationship to obesity and body fat distribution. Klinische Wochenschrift 1991 69 664-668.
Von Eckardstein A & Wu FCW. Testosterone and atherosclerosis. Growth Hormone and IGF Research 2003 13 S72-S84.
Snyder PJ & Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology and Metabolism 1980 51 1335-1339.
Wu FCW & von Eckardstein A. Androgens and coronary artery disease. Endocrine Reviews 2003 24 183-217.
Von Eckardstein S & Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. Journal of Andrology 2002 23 419-425.
Nieschlag E & Behre HM. Pharmacology and clinical uses of testosterone. In Testosterone: Action, Deficiency, Substitution, 2nd edn, pp 293-328 Eds. E Nieschlag & HM Behre. Berlin: Springer-Verlag, 1998.
Elbers JMH & Grootenhuis AJ. New tissue-selective androgens: perspectives in the treatment of androgen deficits. Annals of Endocrinology 2003 64 183-188.
Kumar N, Didolkar AK, Monder C, Bardin CW & Sundaram K. The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology 1992 130 3677-3683.
Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, Bancroft J, Sundaram K, Moo-Young AJ & Baird DT. 7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1999 84 3556-3562.
Anderson RA, Wallace AM, Sattar N, Kumar N & Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7α-methyl-19-nortestosterone in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2003 88 2784-2793.
Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB & Jones TK. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl -8-pyridono[5,6-g-]-quinoline (LG121071). Journal of Medicinal Chemistry 1999 42 210-212.
Rosen J & Negro-Vilar A. New, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle: improved safety profile. Journal of Musculoskeletal and Neuronal Interactions 2002 2 222-224.
Gao W, Chung K, Kearbey JD, Miller DD & Dalton JT. Pharmacologic effects of Androxolutamide (GTx-007) on male rats of varying hormonal status. ENDO 2002 - 84th Annual Meeting of the Endocrine Society (June 19-22, San Fransisco) 2002 Abst P2-487.
